KR20150050983A - Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory - Google Patents

Abstract

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory external application composition for skin containing, as an active ingredient, glucosyl withanolides. The anti-inflammatory cosmetic composition or the anti-inflammatory external application composition for skin according to the present invention exhibits an excellent cyclooxygenase inhibition and inflammation inhibition effect, and are very excellent in cytotoxicity and skin safety compared with conventional anti-inflammatory agents.

Description

The present invention relates to a cosmetic composition and an external composition containing glucosyl withanolides for anti-inflammatory,

The present invention relates to an anti-inflammatory cosmetic composition comprising a glycosyl withanolides as an active ingredient, or an anti-inflammatory external preparation for skin.

Cosmetics are products used to protect the skin and clean the hair, but when the cosmetic composition is examined in detail, ingredients different from the purpose of skin protection are used as an indispensable substance for product formation. For example, surfactants, preservatives, fragrances, sunscreens, pigments, and other ingredients used to impart other benefits or effects. These ingredients are generally known to cause various side effects such as inflammation, rash or edema in the skin (Maibach, H. I., Contact Dermatitis, 6; (1980) 369-404). In addition, sebum components, sweat components, fatty acids in cosmetic components, high-grade alcohols or proteins, which are emitted from the body, are decomposed into highly toxic substances by skin-damaging bacteria existing on the skin, and skin inflammation may be caused by them . Especially in recent years, functional cosmetics have been developed and various functional cosmetics including components such as AHA (alpha hydroxy acid), retinol, and arbutin are commercially available even if there are some side effects on the skin.

To date, substances used for antiinflammatory purposes include nonsteroidal antiinflammatory drugs such as flufenamic acid, ibuprofen, benzydamine or indomethacin, and steroids such as prednisolone and dexamethasone and dexamethasone, and other allantoin, azene, hydrocotizone, licorice acid or derivatives thereof (β-glycyrrhetinic acid or glycyrrhetinic acid derivative) are known to be effective for anti-inflammation Cosmetics, Namsan, p. 162, 1993). However, the use of steroids has been limited due to their safety problems (Kim Chang-jong, Pathology Psychology, Hanlim Sangsaja, p61-69, 1988). Furthermore, indomethacin can not be used in cosmetics, and the licorice acid or its derivative is difficult to stabilize or has poor solubility, so that it is difficult to achieve a practical effect due to the limitation of the concentration in the actual product.

Accordingly, it is an object of the present invention to provide a novel anti-inflammatory cosmetic composition or an anti-inflammatory external preparation for skin which is not only excellent in anti-inflammatory effect but also safe for skin, easily formable as a cosmetic composition or external preparation for skin.

As a means for solving the above problems, the present invention provides a pharmaceutical composition for anti-inflammation or an anti-inflammatory external preparation containing glucosyl withanolides as an active ingredient.

It is known that the above-mentioned urtanide has a sedative effect, a stress inhibitory effect, an antioxidant effect or an immune modulating function of the human body. Meanwhile, the inventors of the present invention found that, in the process of discovering a substance that is not only excellent in anti-inflammatory effect but also safe for skin and easy to be formulated into a cosmetic composition or external preparation for skin, a glucosyl withanolides ) Is excellent in anti-inflammatory effect, has little specific odor, and is a skin-safe ingredient, thus completing the present invention. Through the following examples, the inventors of the present invention confirmed that glycosylated butanolides according to the present invention had excellent cyclooxygenase inhibitory effect and anti-inflammatory effect (Examples 1 and 2). It was also confirmed that skin safety to human body was excellent (Examples 3 and 4).

The glucosyl withanolides according to the present invention may be commercially available products, or may be prepared by a known method through separation, semisynthetic or synthesis from plants. The plant may be, but is not limited to, Winteria cherry (Withania somnifera), Dunalia australis, Datura, Nicandra, Physalis or Rhizomes of Tacca chantrieri have. For example, the glucosyl withanolides may be selected from the group consisting of sitoindoside IX, sitoindoside X, Dunawithanines A, Dunawithanines B, Baimantuoluosides A, Baimantuoluosides B, Baimantuoluosides C, Chantriolides A and Cantriol A, And B (Chantriolides B).

The glucosyl withanolides according to the present invention can be manufactured using commercially available products or based on known methods. The preparation of glucosyl withanolides can be varied within the scope of obvious to a person skilled in the art, and the present invention encompasses the scope thereof. For example, the present invention may be separated or purified from an extract of a plant.

The extraction solvent used to extract glucosyl withanolides from plants may be any solvent selected from water, organic solvents or mixtures thereof, although not limited thereto. The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, ethyl acetate or acetone, or a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane; Or a mixture thereof. For example, the alcohol having 1 to 5 carbon atoms may be selected from methanol, ethanol, propanol, butanol or isopropanol.

The glucosyl withanolides according to the present invention may be fractions obtained by further fractionating the primary extract extracted using the above-mentioned extraction solvent using an extraction solvent having a different polarity. For example, solvents with different polarity may be ether, benzene or hexane.

Two or more kinds of solvents may be used for the fractionation, and the solvent extracts may be sequentially used or mixed according to the polarity of the solvent, but not limited thereto.

The thus-prepared extract or the fraction obtained by performing the fractionation process can then separate or purify the active ingredient according to a conventional separation and purification method. But is not limited to, high performance liquid chromatography (HPLC) can be used.

The glucosyl withanolides prepared by the above method may be in the form of a salt. The salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid , Succinic acid, succinic monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, gluconic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, Methanesulfonic acid-based salts, and methanesulfonic acid-based salts. The inorganic acid may be at least one selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.

Separately, additionally saltable forms include, but are not limited to, the salts of gabapentin, gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, lysine, Aspartate and the like.

In the present invention, the term "inflammation" means a phenomenon appearing for a series of defensive purposes for minimizing the reaction of a cell or a tissue caused by any cause and restoring the damaged region to the original state. , Body fluid reaction, and cell reaction, resulting in pain, edema, redness, fever, etc., resulting in dysfunction. The disease caused by inflammation may be at least one selected from the group consisting of various dermatitis, allergies, systemic lupus erythematosus, retinitis, gastritis, hepatitis, enteritis, pancreatitis and nephritis. The allergies include anaphylaxis, allergic rhinitis allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergies, food allergies and drug allergies.

The inflammation is caused by various biochemical phenomena in vivo. In particular, the inflammation is caused by an enzyme involved in biosynthesis of prostaglandin from arachidonic acid, such as cyclooxygenase (COX) and L-arginine (L- It is known that nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO) from arginine, plays an important role in mediating the inflammatory response.

The term " prostaglandin (PG) "in the present invention is a kind of physiologically active hormone synthesized in the body and has a function of regulating the inflammatory reaction. The prostaglandins are classified into PG1, PG2 and PG3, PG1 and PG3 inhibit inflammation, and PG2 induce inflammation. The prostaglandin is biosynthesized through cyclooxygenase (COX) using arachidonic acid as a precursor.

The term "cyclooxygenase (COX) " in the present invention refers to an enzyme that catalyzes the first step of the synthesis of prostaglandin, wherein two molecules of oxygen are introduced into arachidonic acid to synthesize PG2, and prostaglandin endoperacid It is also called synaptase. Cyclooxygenase-1 (COX-1), which is always present in cells, contains prostaglandins (PGs) required for cytoprotective action, while cyclooxygenase COX-2 is known to play an important role in the inflammatory response by increasing rapidly in the cell during the inflammatory reaction.

The term "nitric oxide (NO)" in the present invention is caused by various cytokines or iNOS induced by external stimuli, and is known to cause cytotoxicity or various inflammatory responses. Chronic inflammation is also known to be associated with increased iNOS activity (Appleton L. et al. Pharmacol., 35. 27-28.1996).

The glycosylated butanolides according to the present invention have a cyclooxygenase (COX) inhibitory activity, and are particularly effective for inflammation mediated by biosynthesis of prostaglandins.

The present invention can provide a desirable anti-inflammatory effect when it comprises an effective amount of glycosylated wtanolid. In the present invention, "effective amount" means an amount capable of exhibiting sufficient cyclooxygenase (COX) inhibitory activity. For example, the effective amount of the saccharified butanoidide contained in the anti-inflammatory composition of the present invention may be 0.001 to 20 parts by weight based on 100 parts by weight of the total composition. For example, 0.001 to 10 parts by weight, 0.01 to 20 parts by weight, 0.01 to 10 parts by weight, and 0.1 to 10 parts by weight. If the saccharified butanolide is contained in an amount of less than 0.001 part by weight, a sufficient anti-inflammatory effect can not be expected. If it is contained in an amount exceeding 20 parts by weight, undesired reactions such as allergy may occur or there may be a problem in skin safety This is to prevent this. The composition is not necessarily limited to this, and may vary depending on the purpose of the composition, the form of the composition, and the condition of the applicant.

On the other hand, the composition of the present invention may contain one or more components which exhibit a known anti-inflammatory effect or a component that enhances the anti-inflammatory effect.

The inclusion of additional anti-inflammatory ingredients may further enhance the anti-inflammatory effect. As anti-inflammatory ingredients known in the art, ibuprofen, flufenamic acid and indomethacin, non-steroid based prednisolone and dexamethasone, other allantoin, , Hydrocortisone, licorice acid, and derivatives thereof. The additional anti-inflammatory component includes all of the above-listed components and analogs thereof exhibiting an equivalent effect thereto. In addition, as a known anti-inflammatory component that can be used in cosmetic compositions, hyaluronic acid, Daphnetin, Glycyrrhizin, Quercetin, Rosmarinic acid, Madecassic acid, , Chamazulene, Bicalein, Emodin, Astaxanthin, norbergenin, 4-O-methylhonokiol, polydatin, ferulic acid, 2-methoxycinnamaldehyde, 2,4-dihydroxyacetophenone, terpinen-4 -ol) and a derivative thereof. [0035] The term " anionic surfactant " The additional anti-inflammatory component may include all of the analogues and plant extracts exhibiting the same effects as those listed above.

The added components may be contained in an amount of 0.0001 to 10 parts by weight based on 100 parts by weight of the total composition. The content of the added components may vary according to requirements such as the activity of cyclooxygenase (COX), skin safety, It can be adjusted.

The cosmetic composition or external preparation for skin according to the present invention can be formulated by a conventional method. For formulation into a skin external preparation, reference may be made to the contents disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and International Cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995, which is incorporated herein by reference in its entirety. Which are incorporated herein by reference.

The cosmetic composition may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, lotion such as soft lotion or nutrition lotion; Lotions such as facial lotion or body lotion; Creams such as nourishing cream, moisture cream or eye cream; essence; Makeup ointment; spray; Gel; pack; Sunscreen; Makeup base; A foundation such as a liquid type, a solid type or a spray type; powder; Make-up removers such as cleansing creams, cleansing lotions or cleansing oils; Or a cleansing agent such as a cleansing foam, a soap or a body wash. The external preparation for skin may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.

The content of the active ingredient may be varied according to the formulation. Examples of the cosmetic composition include a relatively high concentration of the saccharified whitanolide in the case of a wash-off type cosmetic such as a make-up remover or a detergent in which the active ingredient remains on the skin in a short period of time will be. On the other hand, in the case of leave-on type cosmetics such as lotion, cream, essence and the like in which the active ingredient remains on the skin for a long period of time, a lower concentration of saccharified whitanolide than a wash- It may be included.

In addition, it may further include adjuvants or carriers such as stabilizers, solubilizers, vitamins, pigments or fragrances which are conventionally used in cosmetic compositions or external skin preparations. For example, it is possible to use a surfactant such as a fatty substance, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Such as those conventionally used in cosmetic or dermatological preparations, such as, but not limited to, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic active agents, lipophilic active agents, lipid vesicles, Cosmetics, or dermatology, which are commonly used in the art. The components can also be introduced in amounts commonly used in the cosmetics field or the skin science field.

The glucosyl withanolides according to the present invention exhibit excellent cyclooxygenase (COX) inhibition and inflammation inhibitory effects and are superior in cytotoxicity and skin safety to the conventional anti-inflammatory agents.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments and preparations which will be described in detail below. However, it should be understood that the present invention is not limited to the embodiments and manufacturing examples described below, but may be embodied in many different forms and should not be construed as being limited to the exemplary embodiments set forth herein. It is provided to inform the person completely of the scope of the invention.

[Example 1]

Cyclooxygenase (COX) inhibitory effect

In the present invention, cyclooxygenase (COX) was extracted from sheep seminal vesicles of Pel-Freeze. The cyclooxygenase (COX) according to the present invention was prepared by crushing the two hypocotyls and then centrifuging at 3000 rpm for 10 minutes to take up the supernatant. The supernatant was centrifuged at 10000 rpm for 1 hour to separate precipitates, (0.1 M, pH 8.0).

25 μg of hemoglobin is added to 100 mL of Tris buffer solution (0.1 M, pH 8.0) to make a substrate to be 1.1 mM arachidonic acid, and then 10 μl of 10,000 units of cyclooxygenase is added to the substrate. After adding 0.5 ppm, 10 ppm and 50 ppm of citoindoside IX, citoindide X and doina tannin A, respectively, the initial oxygen consumption was measured with a measuring device (Yellow Spring Instrument company, Model 53 oxygen monitor) The activity of the sigenase activity was confirmed. The results are shown in Table 1 below.

Inhibition rate (%) 0.5 ppm 10 ppm 50 ppm (w / w) Cito India Side IX 21 ± 2 34 ± 3 48 ± 4 Cito India Side X 16 ± 3 30 ± 5 46 ± 2 Duane tannin A 19 ± 2 35 ± 4 45 ± 5

n = 3

As shown in the above Table 1, 48% of citoindide IX (50 ppm), 46% of cytoindoide X (50 ppm), 45% of dinahitanein A (50 ppm) were added to the cyclooxygenase at 50 ppm, %, Respectively.

[Example 2]

Anti-inflammatory effect test

(A. Crummey, GP Harper, EA Boyle and FR Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compounds. Agents and Actions 1987: 20: 69 -76) was used to examine the anti-inflammatory effect.

A total of 8 sets of 7 hairless mice (7 mice) were prepared, and both ears of the mice were thoroughly washed with ethanol, and the thickness was measured using a micrometer. A control group coated with a sample containing 1 ppm and 10 ppm of citoindoside IX, citoindoside X, and doenail tannin A, a control group containing 1 ppm of indomethacin, and a control group coated with ethanol Respectively.

In the right ear of the mouse, 2 mg / ear of arachidonic acid was applied to induce inflammation, and in the left ear, ethanol was applied to examine the degree of inflammation caused by the sample itself. After one hour, samples containing 1 ppm and 10 ppm of citoindoside IX, citoindoside X and dinahi tannin A, respectively, were applied to both ears to which ethanol and arachidonic acid were respectively applied. The comparative group contained indomethacin 1 ppm , And the control group was continuously applied to both ears of the mice for 4 days with 20 占 퐇 of ethanol once a day. After 1 hour of application, the degree of edema of both ears was repeatedly measured three times for each ear using a micrometer. Table 2 shows the inhibition rates of swelling of the samples against the control (ethanol), and the inhibition rates of swelling against the comparative group (indomethacin) are shown in Table 3.

sample density Glume (㎛) % Inhibition Before sample treatment After sample treatment Sample group Cito India Side IX 1 ppm 322 493 39.1 10 ppm 321 487 40.9 Cito India Side X 1 ppm 324 506 35.1 10 ppm 320 493 38.4 Duane tannin A 1 ppm 319 493 37.8 10 ppm 324 488 41.6 Comparative group Indomethacin 1.0 325 452 54.8 Control group ethanol 2mg / ear 321 602 -

※ Inhibition rate (%) = (AB) / A x 100

   A: Mean thickness change of the control ear

       (Thickness of ear treated with arachidonic acid - thickness of untreated ear)

   B: Mean thickness change of sample application group ear

(Thickness of sample treated ear - thickness of untreated ear)

Inhibition rate (%) compared to the control group (indomethacin) 1 ppm 10 ppm Cito India Side IX 71% 75% Cito India Side X 64% 70% Duane tannin A 69% 76%

As shown in the above Table 2, at 10 ppm, the degree of inflammation inhibition was 40.9%, 40.4%, 38.4%, and 41.6%, respectively. As shown in Table 3, 75% of cytotoxicide IX, 70% of cytosine X, and 76% of Dunarein tin A showed excellent anti-inflammatory activity against indomethacin at 10 ppm.

On the other hand, when the difference in edema growth rate was significantly different, citoindoside IX, citoindoside X, and norawanthanine A showed a significant difference of 99% with arachidonic acid

[Example 3]

The first human stimulation test (Human patch test)

The first human stimulation test was conducted on 50 healthy adult men and women according to the CTFA guidelines (The Cosmetic, Toiletry and Fragrance Association, Inc., Washington, DC, 20036, 1991).

A sample containing 50 ppm each of citoindoside IX, citoindoside X or doenail tannin A, 1.0% sodium lauryl sulfate and 10% ethanol, a sample containing 1.0% sodium lauryl sulfate and 10% ethanol, and The human irritation was evaluated using 10% ethanol as a sample. Each of the samples was dropped in a Finn chamber (20 占 퐇 each), and the sample was placed on the back of the human body to be tested and fixed with a tape. After 24 hours of application, the patches were removed. After 4 hours from the removal of the patches, the skin reaction of the test site was judged according to the following criteria, and the results are shown in Table 4.

    <Criteria>

      -: No erythema or unusual phenomenon

      ±: slightly redder than around

      +: Significantly reddened than surrounding

    ++: More reddening and swelling than the surrounding area

The number of subjects to be tested is expressed by the following formula: Number of stimuli = [{(占) number 占 1} + {占 number 占 2} + {

sample Number of subjects Judgment result Irritation degree ++ + ± - (50 ppm), sodium lauryl sulfate (1%), ethanol (10%), 50 - - 4 46 0.08 Citoindocide X (50 ppm), sodium lauryl
Sulfate (1%), ethanol (10%), 50 - - 7 43 0.14 (50 ppm), sodium lauryl
Sulfate (1%), ethanol (10%), 50 - - 4 46 0.08 Sodium lauryl sulfate (1%),
Ethanol (10%) 50 2 8 10 30 0.60 Ethanol (10%) 50 - - 10 40 0.20

As can be seen in Table 4 above, cortis indocyanide IX, cortoindoside X and dinahi tannin A significantly relieved the stimulation of sodium lauryl sulfate and ethanol. These results are believed to be due to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect test described above. Thus, it can be concluded that the citoindocide IX, citoindoside X or do-na tannin A according to the present invention is a skin- Able to know.

[Example 4]

Anti-inflammatory sensory test for human body

Ten subjects were randomly assigned to receive a dose of 50 ppm of ceto- indoside IX, ceto- indoside X and do- na-tannin A twice daily for 7 days. Water was used as a control.

The sample (50 ppm) Effective (persons) No change (persons) Cito India Side IX 7 3 Cito India Side X 8 2 Duane tannin A 8 2 water 2 8

As can be seen in Table 5 above, citoindoside IX, citoindoside X, and doña tannin A effectively relieve rashes. These results are believed to be attributable to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect test described above. As a result, it can be concluded that the citoindoside IX, citoindoside X, Able to know.

Hereinafter, the preparation examples (formulation examples) of the cosmetic composition of the present invention are presented, but the following production examples are illustrative of the composition of the present invention, but are not limited thereto.

[Production Example 1]

toilet water

Raw material wt% (w / w)

Glycerin 5.0

Dipropylene glycol 3.0

Hyaluronic acid 0.5

Polyoxyethylene 0.1

Hardened castor oil 0.1

Polyethylene oleyl ethyl ethanol 5.0

Preservative 0.15

Fragrance quantity

Pigment amount

The compound of formula 1 0.1

Purified water to 100

[Production Example 2]

essence

Raw material wt% (w / w)

Cetostearyl alcohol 1.0

Self-emulsifying monostearic acid 1.0

Wax 0.5

Squalane 5.0

Isocetyl octanoate 3.0

Dimethylsiloxane 0.3

Sorbitan monostearate 0.5

Polyethylene glycol monostearate 8.0

Glycerin 4.0

Propylene glycol 0.2

Carboxy polymer 0.22

Triethanolamine 0.25

Antiseptic

Fragrance quantity

Pigment amount

Compound of Formula 1 7.0

Purified water to 100

[Production Example 3]

Lotion

Raw material wt% (w / w)

Cetostearyl alcohol 0.8

Self emulsifying monostearic acid 10

Wax 0.5

Stearic acid 0.5

Liquid paraffin 7.0

Squalane 5.0

Macadamia Oil 3.0

Isocetyl octanoate 2.0

Dimethylsiloxane 0.3

Sorbitan monostearate 0.5

Polyethylene glycol monostearate 1.2

Glycerin 4.0

Propylene glycol 4.0

Betain 4.0

Carboxy polymer 0.12

Triethanolamine 0.15

Preservative 0.25

Fragrance quantity

Pigment amount

Compounds of Formula 1 5.0

Purified water to 100

[Production Example 4]

cream

Raw material wt% (w / w)

Cetostearyl alcohol 3.0

Self emulsifying monostearic acid 1.5

Chin type monostearate 1.5

Wax 0.5

Liquid paraffin 8.0

Squalane 7.0

Isocetyl octanoate 4.0

Tablet Jojoba 4.0

Dimethylsiloxane 0.3

Monostearic acid sorbitan 1.0

Polyethylene glycol monostearate 1.2

Glycerin 6.0

Propylene glycol 4.0

Betain 4.0

Xanthan gum 0.06

Triethanolamine 0.10

Preservative 0.25

Fragrance quantity

Pigment amount

Compound of Formula 1 7.0

Purified water to 100

[Production Example 5]

Gel

Raw material wt% (w / w)

Glycerin 4.0

Propylene glycol 4.0

Ethanol 10

Polyoxyethylene hydrogenated castor oil 0.1

Carboxy polymer 0.30

Triethanolamine 0.30

Antiseptic

Fragrance quantity

Pigment amount

Compound of Formula 1 1.0

Purified water to 100

[Production Example 6]

Ointment

Raw material wt% (w / w)

Cetostearyl alcohol 2.0

Self emulsifying type monostearic acid 2.0

Stearic acid 1.0

Beeswax 4.0

Squalane 7.0

Monostearin glycerin 3.0

Monostearic acid sorbitan 1.0

Polysorbate 80 3.0

Glycerin 5.0

Propylene glycol 4.0

Fragrance quantity

Pigment amount

Compound 10.0

Vaseline to 100

Claims (12)

An anti-inflammatory cosmetic composition comprising glycosyl withanolides as an active ingredient.
The method according to claim 1,
Wherein the glycosyl withanolides is an extract isolated from a plant or obtained through synthesis or semisynthetic.
3. The method of claim 2,
The plants are selected from the group consisting of Winter cherry (Withania somnifera), Dunalia australis, Datura, Nicandra, Physalis and Rhizomes of Tacca chantrieri. &Lt; / RTI &gt;
The method according to claim 1,
The glucosyl withanolides may be selected from the group consisting of citoindoside IX, sitoindoside X, Dunawithanines A, Dunawithanines B, From the group consisting of Baimantuoluosides A, Baimantuoluosides B, Baimantuoluosides C, Chantriolides A and Chantriolides B, At least one selected from the group consisting of:
The method according to claim 1,
Wherein the saccharified glucosyl withanolides is contained in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total cosmetic composition.
The method according to claim 1,
Wherein the anti-inflammatory cosmetic composition has a formulation selected from the group consisting of lotion, milky lotion, cream, essence, cosmetic lotion, spray, gel, pack, sunscreen, makeup base, foundation, powder and detergent.
An anti-inflammatory dermatological agent containing glycosyl withanolides as an active ingredient.
8. The method of claim 7,
Wherein said glycosyl withanolides is an extract isolated from plants or obtained through synthesis or semisynthetic.
9. The method of claim 8,
The plant is selected from the group consisting of Winter cherry (Withania somnifera), Dunalia australis, Datura, Nicandra, Physalis and Rhizomes of Tacca chantrieri. Anti-inflammatory dermatological topical agent.
8. The method of claim 7,
The glucosyl withanolides may be selected from the group consisting of citoindoside IX, sitoindoside X, Dunawithanines A, Dunawithanines B, From the group consisting of Baimantuoluosides A, Baimantuoluosides B, Baimantuoluosides C, Chantriolides A and Chantriolides B, One or more selected anti-inflammatory skin preparations.
8. The method of claim 7,
Wherein the saccharified glucosyl withanolides is contained in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total composition.
8. The method of claim 7,
Wherein the external preparation for skin has a formulation selected from the group consisting of ointments, patches, gels, creams or sprays.